If you want to talk about North United Pharmaceutical, it is still very valuable.

Tens of thousands of acres of land have just been obtained, not counting for the time being, tens of thousands of skilled workers cannot be simply regarded as a burden, no matter how they are all skilled workers.

However, the reality is that there was no shortage of skilled workers in China in the 80s. If it weren't for the establishment of the Chemical Medicine Revitalization Office and the North United Pharmaceutical Industry, the 10,000 workers of the North China Pharmaceutical Industry would have faced unemployment in a few years.

To be more precise, the tens of thousands of workers who are mixed together are like a pile of unsorted dates, if they don't break up, the rotten dates will sooner or later bring the good dates to rot.

Such a Northern United Pharmaceutical Co., Ltd. could be valued at 60 million US dollars, and then receive real money from Jielizen, no one expected.

For Jielizenca, whether it is Northern United Pharmaceutical or the Chemical Drug Revitalization Office, they are not interested, and the only thing they are interested in is the medicine in Yang Rui's hands.

Just the profits from production and sales can make them earn back their capital.

Only the new drug developed by Yang Rui can earn them back $30 million.

Pharmaceutical companies are hungry for new drugs that are difficult for workers in other industries to experience.

There are thousands of pharmaceutical companies in the world, and the pharmaceutical companies that have the ability to develop new drugs are usually within 100, except for single-digit generic drug companies, the remaining double-digit pharmaceutical companies can only put three or five pure new drugs on the market every year.

At this time, whoever holds the new medicine is simply in control of life and death.

Not in a symbolic sense, but in fact the power of life and death.

For example, Gaucher disease, although it is a rare disease, is also a rare disease with a high incidence, the number of patients in the world is hundreds of thousands, but in the absence of suitable drugs, the life cycle of Gaucher patients is only 10 years after the onset of the disease, and basically will not exceed 20 years.

At this time, there is also a message that everyone does not want to think about, if there is really a special drug, there will not be only hundreds of thousands of Gaucher patients in the world.

And with so many people, it is obviously impossible to get medicine all at once.

Even from a security point of view, countries will not allow new drugs to be rolled out in their homes in one go.

At this point, the pharmaceutical companies are actually in control of the life and death of these Gaucher patients.

Wherever they apply for marketing first, Gaucher patients in that country can be treated early, which not only means better survival, but also less suffering and a better quality of life.

No one wants to drag a sick body to live.

From the perspective of consumers and hospitals, they also expect a specific drug to appear.

Pharmaceutical companies that can always produce new and good drugs will be more popular with hospitals and doctors, which is a forced qualification that belongs exclusively to pharmaceutical companies. When necessary, pharmaceutical companies can even bundle and stipulate that as many generic drugs as they buy......

In places where regulations are not strict, whoever holds the power of life and death is qualified to make money.

How much is 500,000 lives worth?

Is $100 a person too much?

Is $200 expensive for one person?

In the modern consumer system, production costs are only a small fraction for pharmaceutical companies, and sales, R&D and management costs are the most expensed.

A new drug may not be able to make pharmaceutical companies rich in one go, and blockbusters with annual sales of $1 billion are a minority after all, but a steady stream of new drugs is the meaning of the survival of pharmaceutical companies.

It is not only the meaning of the survival of pharmaceutical companies themselves, but also the perception of the public, society and the country.

If a pharmaceutical company can't produce a new drug in five years, no matter whether it makes it itself or buys it, even if it makes a lot of money in other income, investors will always worry about it.

If a pharmaceutical company can't produce a new drug in 10 years, even if the investors themselves don't say it, the company itself will not be able to survive.

In an industry that sells health and lives, there are simply too many ways for pharmaceutical companies to make money.

Some special rare drugs, which can be prescribed for millions of dollars per year, can be called perverted. Pharmaceutical companies in war-torn areas have never shown up with benevolent faces. Pharmaceutical companies in the bustling city are even more adept at doing flies and dogs.

However, no matter how the pharmaceutical companies want to make money, you must first have the medicine in your hands.

New drugs with a 15-year patent period and rare drugs with a 25-year patent period are weapons in the hands of pharmaceutical companies.

As much as a 15-year-old boy is willing to pay for his Rogue weapon, a pharmaceutical company is willing to pay for a new drug.

The careful thinking of Northern United Pharmaceutical, under the pressure of Jielikang, disappeared without a trace like ice and snow falling on the oven.

However, the funds allocated to the Ion Channel Laboratory in advance were still only a pitiful $200,000.

In the words of Comrade Wang Gaohan, the new general manager of North United Pharmaceutical Co., Ltd.: "Use it first, if it's not enough, say hello again, and the money will come." ”

The project team responsible for making recombinant DNA was naturally complaining, and Gu Qiang even complained: "$200,000 is not even enough money to buy a fluorescence plate reader, so it doesn't need to start, it's over." ”

The specific drug for Gaucher disease chosen by Yang Rui is an enzyme alternative, and it is as simple as that to supplement the enzyme for people who are deficient in enzymes.

However, it is extremely difficult to make a grape cerebrosidase that is suitable for the human body – and regardless of how this step is performed, an instrument such as a fluorescence plate reader is a must.

Glutinosebral glycoenzyme is not visible to the human eye.

In addition, higher resolution UV/Vis spectrophotometers, new electrophoresis instruments with higher efficiency, etc., are also indispensable expenses.

While labs can share these commonly used equipment, it is clearly not the right choice to grab instruments in the tight time frame of new drug development.

In addition, the size of the ion channel laboratory is growing, and it is inevitable that new instruments will be added to new projects, even if they are duplicates. It's like the simplest microscope, you can't wait in a group of lab dogs to use it.

Some project teams in China are poor and have no choice, and Yang Rui is not ready to let the ion channel laboratory live the hard life of queuing up at two o'clock in the morning to wait for instruments.

Who loves whom in the past.

"Take the money from the lab's ledger and return $200,000 to them. Yang Rui quickly made a decision, called Xu Zhengping again, and said: "You go to contact a foreign appraisal company to evaluate the price of the alternative to grape cerebrosidase carried out by our current recombinant DNA project team." ”

"What's that?" Xu Zhengping was stunned.

"It's to find a foreigner company to come over and let them see how much these things made by our project team are worth in the market. Yang Rui paused for a moment and said: "The people of Northern United Pharmaceutical are used to the life of state-owned enterprises, and they still think about taking research results at cost price." 200,000 to 2 million is just to buy a headhead. ”

Xu Zhengping hesitated to find it, he didn't know how strong Yang Rui's decision was on the oppression of North United Pharmaceutical, in fact, there are basically no domestic companies that can experience this now.

In this era when there are research institutes under enterprises, the value of research results has always fluctuated at cost price.

It's a pity that Yang Rui is not ready to talk to them about the cost.

How much it costs is my business, and the price is determined by the value.

Remember the mobile version URL: m.